Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.
Patients have been given single oral doses of the radiosensitiser Ro-07-0582 and serum concentrations have been attained in the range expected to be of value in radiosensitisation. Immediate gastrointestinal side effects appear to limit the dose to below 140 mg/kg but radiosensitising serum levels of approximately 200 mug/ml can be attained. Tolerance may be improved by giving anti-emetics and a more palatable preparation. Estimates of the concentration of Ro-07-0582 in tumour have ranged from 12 to 92% of the serum concentration at the time of determination.
D000328:Adult; D000368:Aged; D001706:Biopsy; D001943:Breast Neoplasms / Q000532:radiotherapy; D002277:Carcinoma / Q000032:analysis / Q000532:radiotherapy; D002986:Clinical Trials as Topic; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D009362:Neoplasm Metastasis; D009422:Nervous System Diseases / Q000209:etiology; D009460:Neurologic Examination; D009593:Nitroimidazoles / Q000009:adverse effects* / Q000032:analysis / Q000097:blood; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects*; D011859:Radiography; D012509:Sarcoma / Q000032:analysis / Q000532:radiotherapy; D012886:Skull / Q000000981:diagnostic imaging; D013649:Taste; D014839:Vomiting / Q000209:etiology
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents